Haleon PLC Sponsored ADR

HLN Healthcare Drug Manufacturers Specialty & Generic

Haleon PLC Sponsored ADR’s revenue for fiscal 2025 (year ended December 2025) was $14.5 billion, up 1.33% from fiscal 2024.

9.12 0.03 −0.33%
Market cap
$40.2B
P/E
20.5×
Fwd P/E
16.5×
Dividend yield
2.17%
F-score
8/9
Altman Z
3.04
Beneish M
−2.60
Dividend safety
63/100

Haleon PLC Sponsored ADR (HLN) P/E ratio

Alert me on P/E ratio

As of 6 November 2026, Haleon PLC Sponsored ADR (HLN) trades at a P/E ratio of 20.5×. Over the past ten years it has ranged from 19.2× (October 2026) to 26.3× (September 2024); the current reading is higher than 12% of that period. That is in line with the Drug Manufacturers Specialty & Generic industry median of 20.5× and below the Healthcare sector median of 24.5×.

P/E ratio, daily

Embed this chart

Annual newest first

Period P/E ratio Change
FY2025 22.7× 5.97%
FY2024 21.4× 4.13%
FY2023 20.5× 0.00%
FY2022 20.5× 0.00%
FY2021 20.5× 0.00%
FY2020 20.5× 0.00%
FY2019 20.5× —

Quarterly newest first

Period P/E ratio Change
Sep 2024 23.7× 15.48%
Mar 2024 20.5× 0.00%
Sep 2023 20.5× 0.00%
Jun 2023 20.5× 0.00%
1 more quarters

Against its own ten years

Low 19.2× High 26.3×
Ten-year median 21.9×
Current reading's percentile 12

P/E ratio against peers

Company P/E ratio
VTRS Viatris Inc. compare n/m
ELAN Elanco Animal Health Incorporated compare n/m
ZTS Zoetis Inc. compare 13.5×
UTHR United Therapeutics Corporation compare 19.6×
HLN Haleon PLC Sponsored ADR 20.5×
NBIX Neurocrine Biosciences, Inc. compare 23.6×
TAK Takeda Pharmaceutical Co. compare 31.6×
RDY Dr. Reddy's Laboratories Ltd compare 45.4×
TEVA Teva Pharmaceutical Industries Ltd. compare 93.7×
Drug Manufacturers Specialty & Generic industry median 20.5×
Healthcare sector median 24.5×
Market median 17.8×

What P/E ratio is

Price to Earnings Ratio shows how much investors pay for each dollar of a company’s annual profit per share.

Stock Price ÷ EPS (Basic) (TTM)

The full definition of P/E ratio →

More on HLN